Clinical trials: Immunity
Hepatitis C
Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
The purpose of this study is to determine if hepatitis C virus and influenza virus vaccine components can cross the placenta and stimulate an immune response in the fetus.
- Trial name
- NCT00810875
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Malaria,Falciparum
A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants
This is a clinical trial to evaluate the safety and immunogenicity of R21/MM in healthy Kenyan participants from the different age groups.Participants will receive 3 vaccinations 4 weeks apart.
- Trial name
- NCT03580824
- Testing
- R21 in Matrix- M adjuvant vaccine
- Where
- Kenya
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Immunology, Nephrology
Immune Response to Influenza Vaccine in ESRD Patients
On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients.
- Trial name
- NCT04122222
- Testing
- Influenza vaccine
- Volunteers
- 60 people
- Sponsor
- Mahidol University
Hernia
BP as a Super-light Mesh and as a New Fixation Device for General Surgery -DM108/2008-B
The Buckypaper (BP) is an innovative material that has attracted the attention of many research groups engaged in the study of its possible applications in various technological fields.
- Trial name
- DM108/2008-B (NCT02341222)
- Testing
- BP self-standing felt device, PR Parietene mesh device
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Roma La Sapienza
HIV Infections, Influenza
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents.
- Trial name
- NCT00091702
- Testing
- Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV)
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tetanus, Acellular Pertussis
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00148941
- Testing
- SB213503 lot 1, SB213503 lot 2, SB213503 lot 3
- Where
- 24 sites in United States
- Volunteers
- 4,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis, Respiratory Tract Infections
Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)
The purpose of this study is determine if high-dose vitamin D supplementation improves clinical outcomes related to lung function and immunity in patients with Cystic Fibrosis who are admitted to the hospital with an acute lung…
- Trial name
- DISC (NCT01426256)
- Testing
- Cholecalciferol
- Where
- 5 sites in United States
- Volunteers
- 91 people
- Sponsor
- Emory University
Immunity, Cellular, Hypersensitivity, Delayed Type
Immune Responses to BCG Vaccination in Malawi and the UK
BCG vaccination has been found to provide greater protection against TB in the UK than in Malawi. This study compares immune responses in BCG-vaccinated and unvaccinated teenagers and young adults in Malawi and in the UK.
- Trial name
- NCT00241657
- Testing
- BCG
- Where
- 2 sites in Malawi, United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Respiratory Syncytial Virus Infections
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children.
- Trial name
- NCT02040831
- Testing
- RSV LID ΔM2-2 Vaccine
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID - 19
Retail COVID-19 Study
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection.
- Trial name
- NCT06761612
- Testing
- FDA approved mRNA vaccines
- Where
- 20 sites in United States
- Volunteers
- 2,519 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Anaemia, Malaria
Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania
The proposed study has as the main objective to investigate the effect of schistosome and STH infections and the effect of an anthelminthic intervention on P.
- Conditions
- Anaemia, Malaria, Hepatosplenomegaly
- Trial name
- NCT00347113
- Testing
- Albendazole and praziquantel
- Where
- Tanzania
- Volunteers
- 620 people
- Sponsor
- DBL -Institute for Health Research and Development
Healthy
Normal Human Electro-Oculogram
This study will measure the normal range of the human electro-oculogram (EOG) in people of various age groups. EOGs are recordings of electrical signals generated by the retina (the light-sensitive tissue in the back of the eye)…
- Trial name
- NCT00001610
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV - Anogenital Human Papilloma Virus Infection, HIV Infections
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
Phase IV prospective study measuring the immunogenicity (neutralizing antibody titles against each HPV vaccine genotype) of the 9-valent vaccine against HPV (Gardasil9®Merck) in HIV-positive women aged 15-40 years with fully…
- Trial name
- Papillon (NCT03391921)
- Testing
- Vaccine
- Where
- Belgium
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Trauma, Burns
Inflammation and the Host Response to Injury (Burns)
The purpose of this study is to help improve our understanding of the biology involved in the body's response to serious trauma or burn injury.
- Conditions
- Trauma, Burns, Multiple Organ Failure
- Trial name
- NCT00257244
- Where
- 4 sites in United States
- Volunteers
- 280 people
- Sponsor
- Massachusetts General Hospital
Acute Respiratory Tract Infections
FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test
The aim of this study is to determine performance characteristics of the FebriDx test in predicting viral or bacterial infection etiology among febrile (observed or reported) patients presenting the emergency department, urgent…
- Trial name
- NCT02018198
- Testing
- FebriDx
- Where
- 20 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Rapid Pathogen Screening
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
Allergic Rhinitis (AR)
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS
Background Allergic Rhinitis is a chronic Th2-mediated inflammatory disorder associated with significant disease burden and impaired quality of life.
- Trial name
- ARAM (NCT07626099)
- Testing
- AYURVEDA treatment protocol, Control(Citrizine 10mg)
- Volunteers
- 104 people
- Sponsor
- Amrita Vishwa Vidyapeetham
Familial Mediterranean Fever, MEFV Gene Mutation
Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
Familial Mediterranean fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is caused by mutations in the MEFV gene, which encodes variants of the Pyrine inflammasome.
- Trial name
- DEPIST-FMF 2 (NCT04478409)
- Testing
- one additional blood sample during a planned blood test
- Where
- 8 sites in France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hand Foot and Mouth Disease
Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months
This study evaluates the safety,three batches consistency and immunity duration of the post-marketing inactivated Enterovirus Type 71 (EV71) vaccine in children aged 6-71 months.This study has two groups:safety observation group…
- Trial name
- NCT02889497
- Testing
- the first batch vaccine, the second batch vaccine, the third batch vaccine
- Volunteers
- 20,900 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention